...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Osteoarthritis and cartilage >The potential of induced pluripotent stem cells as a tool to study skeletal dysplasias and cartilage-related pathologic conditions
【24h】

The potential of induced pluripotent stem cells as a tool to study skeletal dysplasias and cartilage-related pathologic conditions

机译：诱导多能干细胞的潜力作为研究骨骼发育不良和软骨相关病理条件的工具

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The development of induced pluripotent stem cells (iPSCs) technology has opened up new horizons for development of new research tools especially for skeletal dysplasias, which often lack human disease models. Regenerative medicine and tissue engineering could be the next areas to benefit from refinement of iPSC methods to repair focal cartilage defects, while applications for osteoarthritis (OA) and drug screening have evolved rather slowly. Although the advances in iPSC research of skeletal dysplasias and repair of focal cartilage lesions are not directly relevant to OA, they can be considered to pave the way to future prospects and solutions to OA research, too. The same problems which face the present cell-based treatments of cartilage injuries concern also the iPSC-based ones. However, established iPSC lines, which have no genomic aberrations and which efficiently differentiate into extracellular matrix secreting chondrocytes, could be an invaluable cell source for cell transplantations in the future. The safety issues concerning the recipient risks of teratoma formation and immune response still have to be solved before the potential use of iPSCs in cartilage repair of focal cartilage defects and OA. (C) 2016 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
机译：诱导多能干细胞（IPSCS）技术的发展开辟了新的研究工具的新视野，尤其是对于骨骼发育不良，通常缺乏人类疾病模型。再生医学和组织工程可以是下一个区域，从细化IPSC方法来修复局灶性软骨缺陷，而骨关节炎（OA）和药物筛选的应用相当缓慢地发展。虽然IPSC骨骼发育不良和局灶性软骨病变修复的研究进展与OA不直接相关，但它们也可以考虑为未来的前景和解决方案铺平了OA研究。面对当前细胞的软骨损伤治疗问题的同样问题也涉及IPSC的基于IPSC的处理。然而，建立了没有基因组畸变并且有效地分化为细胞外基质的细胞间畸形的IPSC线路可能是未来细胞移植的无价细胞源。在局灶性软骨缺陷和OA软骨修复的潜在使用之前，必须解决有关畸胎瘤形成和免疫反应的受体风险的安全问题。 （c）2016年骨关节炎研究协会国际。 elsevier有限公司出版。保留所有权利。

著录项

  • 来源
    《Osteoarthritis and cartilage》 |2017年第5期|共9页
  • 作者

    Liu H.; Yang L.; Yu F. F.; Wang S.; Wu C.; Qu C.; Lammi M. J.; Guo X.;

  • 作者单位

    Xi An Jiao Tong Univ Sch Publ Hlth Hlth Sci Ctr Key Lab Trace Elements &

    Endem Dis Natl Hlth &

    Xi An Jiao Tong Univ Sch Publ Hlth Hlth Sci Ctr Key Lab Trace Elements &

    Endem Dis Natl Hlth &

    Xi An Jiao Tong Univ Sch Publ Hlth Hlth Sci Ctr Key Lab Trace Elements &

    Endem Dis Natl Hlth &

    Xi An Jiao Tong Univ Sch Publ Hlth Hlth Sci Ctr Key Lab Trace Elements &

    Endem Dis Natl Hlth &

    Xi An Jiao Tong Univ Sch Publ Hlth Hlth Sci Ctr Key Lab Trace Elements &

    Endem Dis Natl Hlth &

    Umea Univ Dept Integrat Med Biol S-90187 Umea Sweden;

    Xi An Jiao Tong Univ Sch Publ Hlth Hlth Sci Ctr Key Lab Trace Elements &

    Endem Dis Natl Hlth &

    Xi An Jiao Tong Univ Sch Publ Hlth Hlth Sci Ctr Key Lab Trace Elements &

    Endem Dis Natl Hlth &

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 骨科学（运动系疾病、矫形外科学）;
  • 关键词

    Osteoarthritis; Induced pluripotent stem cells; Regenerative medicine; Drug screening;

    机译：骨关节炎;诱导多能干细胞;再生医学;药物筛选;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号